Dennis M. Lanfear is a seasoned biotechnology executive who currently serves as the President, Chief Executive Officer, and Chairman of the Board of Directors at Coherus BioSciences, Inc. With a career spanning several decades in the biopharmaceutical industry, Lanfear has a proven track record of leadership and innovation. He joined Coherus BioSciences in 2012 and has been instrumental in steering the company towards its goal of developing and commercializing high-quality biosimilar and immuno-oncology therapeutics. Under his leadership, Coherus has successfully brought several products to market, including UDENYCA, a biosimilar to Neulasta, and CIMERLI, a biosimilar to Lucentis. Prior to his role at Coherus BioSciences, Lanfear held various leadership positions at other prominent biotechnology companies. He was the President and CEO of Amgen, Inc., where he played a key role in the development and commercialization of several blockbuster drugs. Lanfear also served as the Executive Vice President of Sales and Marketing at Amgen, where he was responsible for driving the company's global commercial strategy. His extensive experience in the industry, coupled with his strategic vision, has been vital in positioning Coherus BioSciences as a leader in the biosimilar and immuno-oncology markets. As the President, CEO, and Chairman of the Board at Coherus BioSciences, Lanfear oversees the company's overall strategy and operations. He is committed to advancing the company's mission of improving patient access to high-quality, cost-effective biologic therapies. Under his guidance, Coherus continues to expand its product pipeline and strengthen its position in the competitive biopharmaceutical landscape. Lanfear's leadership has been recognized with numerous accolades, including being named one of the "Top 25 Biotech CEOs" by FierceBiotech. His dedication to innovation and patient care continues to drive Coherus BioSciences forward in its pursuit of transforming the treatment landscape for patients worldwide.